Gefitinib Accord

Gefitinib Accord is an oral medication used to treat certain types of cancer. This pharmaceutical is manufactured by Accord Healthcare B.V. and is designed for targeted therapy.

Gefitinib Accord is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific genetic markers. It works by targeting and inhibiting the growth of cancer cells. Patients often wonder, 'What is Gefitinib used for?' This medication is specifically indicated for advanced or metastatic NSCLC with EGFR mutations.

Common effects of Gefitinib Accord may include skin rash, diarrhea, and fatigue. Some users might experience nausea or loss of appetite. These effects can vary in intensity and duration among individuals.

Gefitinib Accord should be handled with care, especially by pregnant women or those planning to become pregnant. It is important to follow the advice of a healthcare professional regarding its use. Always store the medication as directed to maintain its efficacy.

Gefitinib Accord may interact with certain medications, including those that are metabolized by the liver. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional.